Immune Checkpoint Inhibitors in Lung Cancer: Role of Biomarkers and Combination Therapies

Lung cancer is the leading cause of cancer-related death worldwide, with a poor prognosis. Despite aggressive treatment, progression-free survival (PFS) and overall survival are limited. Recently, various kinds of immune checkpoint inhibitors (ICIs) have emerged for several cancers, targeting PD1, P...

Descripción completa

Detalles Bibliográficos
Autores principales: Maung, Tun Zan, Ergin, Huseyin Ekin, Javed, Mehwish, Inga, Evelyn E, Khan, Safeera
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292688/
https://www.ncbi.nlm.nih.gov/pubmed/32542150
http://dx.doi.org/10.7759/cureus.8095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292688/
https://www.ncbi.nlm.nih.gov/pubmed/32542150
http://dx.doi.org/10.7759/cureus.8095

Ejemplares similares